Successful testing of a biosimilar drug against 11 types of cancer in Russia

Russian scientists have announced the completion of clinical trials for a biosimilar analog of one of the world's leading oncology treatments - pembrolizumab. This drug is widely used to fight eleven different types of cancer, including the most aggressive forms.

The creation of the biosimilar became possible thanks to modern technologies for producing monoclonal antibodies and multi-stage quality control at all development phases. Projects for drugs under patent protection are already prepared, and production launch is planned immediately after the patents expire.

According to specialists, the Russian biosimilar demonstrates effectiveness and safety comparable to the original, which is confirmed by clinical trial results. The introduction of such medications will help expand access to modern treatment methods and reduce the financial burden on the healthcare system.

The development of domestic biosimilars opens new perspectives in the fight against oncological diseases and makes advanced therapy methods more accessible for Russian patients.